High Rate of Durable Responses with Undetectable Minimal Residual Disease with Front-Line Venetoclax and Rituximab in Young, Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biological Profile: Results of the Gimema Phase II LLC1518 – Ve

By
Jamie Kang
-
0
180
The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of front-line, fixed-duration venetoclax and rituximab in combination in young, fit patients with chronic lymphocytic leukemia and unmutated IGHV and/or TP53 disruption.
[Haematologica]
Abstract